AstraZeneca COVID-19 Jab Shows 74% Efficacy In US Trial
- Reuters reported that large U.S. trial results of AstraZeneca Plc's (Get Free Alerts for AZN) COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease.
- In people aged 65 and older, the efficacy increased to 83.5%
- Overall efficacy of 74% was lower than the interim 79% reported in March, a result AstraZeneca revised days later to 76% after a rare public rebuke from health officials that the figure was based on "outdated information."
- The study included data from more than 26,000 volunteers in the United States, Chile, and Peru.
- There were no cases of severe or critical symptomatic COVID-19 among the more than 17,600 participants who got the vaccine, compared with 8 cases among the 8,500 volunteers on placebo.
- There were also two deaths in the placebo group but none among those who received the vaccine.
- "I was pleasantly surprised," Dr. Anna Durbin, a vaccine researcher at Johns Hopkins University and one of the study's investigators, said of the overall result. "It was also highly protective against severe disease and hospitalization," she said.
- No blood clotting side effects linked to the vaccine were observed during the study.
- AstraZeneca said it plans to file for full approval with the FDA rather than seek emergency use authorization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.